REG - BioVentix PLC - Notice of AGM

BioventixAnnouncement

08/11/2024 08:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241108:nRSH5124La&default-theme=true

RNS Number : 5124L  BioVentix PLC  08 November 2024

Bioventix plc

("Bioventix" or the "Company")

 

Posting of Annual Report and Notice of AGM

 

Bioventix plc (AIM: BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that it has posted its Annual Report for the
year ended 30 June 2024 together with a Notice of Annual General Meeting
("AGM") and Form of Proxy to shareholders that have elected to receive
documentation in hard copy format. The documents will also be available from
the Company's website at www.bioventix.com under the Investors section.

 

The Company's AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on
Thursday 5 December 2024 at 2.00pm.

 

For further information please contact:

 Bioventix plc                                      Tel: 01252 728 001
 Peter Harrison            Chief Executive Officer

 Cavendish Capital Markets Limited                  Tel: 020 7220 0500
 Geoff Nash/Abigail Kelly  Corporate Finance
 Nigel Birks/Harriet Ward  ECM

 

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGRBDBRUGDGSI